Local Consolidative Therapy Shows No Survival Benefit After Dual Immunotherapy in Metastatic Lung Cancer
Source Summary
Local consolidative therapy (LCT) failed to improve survival outcomes in patients with metastatic non-small cell lung cancer (NSCLC) who received induction treatment with nivolumab plus ipilimumab. The finding applies across patient subgroups studied.
Why it matters
This trial result indicates that adding local consolidative therapy to dual immunotherapy does not provide additional survival benefit for metastatic NSCLC patients.
